Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NAT1 | P18440 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473898 | 0.82 | CDK1 (0.68) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL13918111 | 0.80 | IKBKB (0.54) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL5510994 | 0.78 | CA12 (0.50) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL4466766 | 0.72 | CDK2 (0.62) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL4467252 | 0.71 | CDK2 (0.64) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL4475239 | 0.71 | CDK2 (0.62) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL4476707 | 0.71 | CDK2 (0.62) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL13931766 | 0.71 | CDK2 (0.48) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL4466637 | 0.70 | CDK2 (0.65) | CA1CA2CA9CA12CDK1 | |
| SCHEMBL13932210 | 0.70 | CDK2 (0.48) | CA2CA9CDK1CDK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | claimed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | claimed |
| US-7507834-B2 | Substituted anilinopyrazoles | SMITHKLINE BEECHAN CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1597234-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20060142284-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142284-A1 | Novel compounds | CDK2, CDK3, CDK2AP2 | CA1 4733/4885CA2 4207/4885CA9 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.